| アイテムタイプ |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-01-20 |
| タイトル |
|
|
タイトル |
Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
rheumatoid arthritis |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
interstitial lung disease |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
RA-ILD |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
JAK inhibitors |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
methotrexate |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
epithelial-mesenchymal transition |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Kurushima, Shota
Koga, Tomohiro
Umeda, Masataka
Iwamoto, Naoki
Miyashita, Ritsuko
Tokito, Takatomo
Okuno, Daisuke
Yura, Hirokazu
Ishimoto, Hiroshi
Kido, Takashi
Sakamoto, Noriho
Ueki, Yukitaka
Mukae, Hiroshi
Kawakami, Atsushi
|
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Objectives: Little is known about how various treatments impact the progression of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients. Here, we compared ILD progression in RA patients treated with Janus kinase inhibitors (JAKi) or biological disease-modifying anti-rheumatic drugs (bDMARDs). In vitro experiments were also performed to evaluate the potential effects of the drugs on epithelial–mesenchymal transition (EMT), a key event in pulmonary fibrosis. Methods: This retrospective study included 93 RA-ILD patients who initiated treatment with JAKi, tumour necrosis factor inhibitors (TNFi), or abatacept between 2017 and 2020. Worsening ILD was quantified by changes in chest computed tomography (CT) scans between baseline and follow-up (mean 14 months, range 6–51 months). Response to treatment was evaluated using Disease Activity Score-28 with erythrocyte sedimentation rate (DAS28-ESR). Expression of the EMT marker N-cadherin in A549 lung cells was assessed by western blotting. Results and discussion: Worsening ILD was detected in 19.4% (7/36), 16.7% (5/30), and 22.2% (6/27) of patients treated with JAKi, abatacept, and TNFi, respectively. Multivariate analysis identified female gender (P=0.043) and >10% fibrotic lesions (P=0.015) as significant predictors of worsening ILD. DAS28-ESRbased non-responder status was also significantly associated with worsening ILD (P=0.0085). In vitro, combination treatment with methotrexate and baricitinib significantly impeded EMT progression. Worsening ILD was associated with more extensive fibrotic lesions at baseline and female gender in RA patients treated with JAKi or bDMARDs. JAKi and methotrexate co-treatment may prove beneficial in modifying key events underlying the pathogenesis of RA-ILD. |
|
言語 |
en |
| 書誌情報 |
en : Frontiers in Immunology
巻 15,
p. art. no. 1501146,
発行日 2024-12-16
|
| 出版者 |
|
|
出版者 |
Frontiers Media SA |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1664-3224 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.3389/fimmu.2024.1501146 |
| 権利 |
|
|
権利情報 |
© 2024 Kurushima, Koga, Umeda, Iwamoto, Miyashita, Tokito, Okuno, Yura, Ishimoto, Kido, Sakamoto, Ueki, Mukae and Kawakami. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
|
言語 |
en |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 引用 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Frontiers in Immunology, 15, art. no. 1501146; 2024 |
|
言語 |
en |
FI15_1501146.pdf (1 MB)
